The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436).
K. L. Nathanson
Research Funding - GlaxoSmithKline
A. Martin
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
R. Letrero
No relevant relationships to disclose
K. P. D'Andrea
No relevant relationships to disclose
S. O'Day
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
J. R. Infante
No relevant relationships to disclose
G. S. Falchook
Research Funding - GlaxoSmithKline
Other Remuneration - GlaxoSmithKline
M. Millward
Research Funding - GlaxoSmithKline
C. M. Curtis
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
B. Ma
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
R. C. Gagnon
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
P. F. Lebowitz
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
G. V. Long
Consultant or Advisory Role - GlaxoSmithKline (U)
R. F. Kefford
Consultant or Advisory Role - GlaxoSmithKline
Other Remuneration - GlaxoSmithKline